Oppenheimer Lowers UroGen Pharma (NASDAQ:URGN) Price Target to $10.00

UroGen Pharma (NASDAQ:URGN - Free Report) had its price objective trimmed by Oppenheimer from $36.00 to $10.00 in a research report report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

URGN has been the topic of a number of other reports. HC Wainwright downgraded shares of UroGen Pharma from a "buy" rating to a "neutral" rating in a report on Thursday, May 22nd. The Goldman Sachs Group lowered their price objective on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Thursday, May 8th. Finally, Scotiabank started coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, UroGen Pharma has a consensus rating of "Moderate Buy" and a consensus target price of $23.14.

UroGen Pharma Price Performance

Shares of URGN stock traded down $0.08 during trading hours on Tuesday, reaching $4.92. 1,759,514 shares of the company were exchanged, compared to its average volume of 738,328. The stock's fifty day moving average is $8.99 and its two-hundred day moving average is $10.28. UroGen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $20.70. The company has a market cap of $226.85 million, a price-to-earnings ratio of -1.56 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. Sell-side analysts forecast that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Institutional Trading of UroGen Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC grew its stake in shares of UroGen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after acquiring an additional 5,140 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the fourth quarter valued at approximately $59,000. Lazard Asset Management LLC acquired a new position in shares of UroGen Pharma during the 4th quarter worth approximately $67,000. GAMMA Investing LLC raised its stake in shares of UroGen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after buying an additional 7,392 shares during the period. Finally, Aquatic Capital Management LLC acquired a new position in UroGen Pharma in the 4th quarter valued at $101,000. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.